Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Acquired by Barclays PLC

Barclays PLC lifted its holdings in shares of Repare Therapeutics Inc. (NASDAQ:RPTX) by 1,471.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,330 shares of the company’s stock after buying an additional 7,800 shares during the period. Barclays PLC’s holdings in Repare Therapeutics were worth $29,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in RPTX. Vontobel Holding Ltd. boosted its stake in shares of Repare Therapeutics by 20.0% during the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after buying an additional 4,000 shares during the period. XTX Topco Ltd acquired a new stake in shares of Repare Therapeutics during the second quarter worth about $110,000. Exchange Traded Concepts LLC boosted its stake in shares of Repare Therapeutics by 21.2% during the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after buying an additional 8,809 shares during the period. Stifel Financial Corp boosted its stake in shares of Repare Therapeutics by 36.4% during the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after buying an additional 13,800 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Repare Therapeutics during the second quarter worth about $273,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

Repare Therapeutics Trading Up 7.8 %

Shares of Repare Therapeutics stock opened at $1.38 on Friday. Repare Therapeutics Inc. has a 12-month low of $1.20 and a 12-month high of $8.49. The stock has a market cap of $58.67 million, a PE ratio of -0.69 and a beta of 0.88. The company has a 50-day moving average of $2.47 and a two-hundred day moving average of $3.03.

Wall Street Analyst Weigh In

RPTX has been the subject of a number of recent analyst reports. Lifesci Capital restated a “market perform” rating on shares of Repare Therapeutics in a research report on Friday, December 13th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Repare Therapeutics in a research report on Friday, November 8th. Finally, Stifel Nicolaus reduced their price objective on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, December 13th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.